Melanoma: Clinical Trials & Research

Pictured: Paul Chapman
Video

Medical oncologist Paul Chapman of Memorial Sloan Kettering describes cutting-edge research to improve the treatment of metastatic melanoma.

(08:00)

One of the many benefits we can offer our patients is the chance to participate in clinical trials, which are research studies that test the safety and effectiveness of new ways to diagnose and treat cancer. At any given time, our investigators are conducting hundreds of trials. If you’re eligible to take part, you may have access to new options that aren’t widely available elsewhere.

Through our research, we’ve made enormous strides in treating melanoma, dramatically improving the chance for survival and a high quality of life for many people with the illness. Many of our patients choose to take part in these studies.

As a result of clinical trial findings, MSK has made major advances in two areas in particular: the development of immunotherapies that boost your immune system’s ability to fight cancer, such as ipilimumab (Yervoy™), and targeted therapies that home in on specific defects in your individual cancer, blocking the growth of cancer cells while sparing most normal, healthy cells.

We continue to conduct trials with ipilimumab and other experimental immunotherapies and targeted therapies, and we are experts at selecting the investigational therapies most likely to benefit you.

Review the list of current studies below to learn more about a particular study.

Showing 24 trials
Title Investigatorsort icon
A Phase II Study of Ipilimumab Plus Isolated Limb Infusion with Melphalan and Dactinomycin to Treat Advanced Unresectable Melanoma of the Extremity
[Protocol 10-101]
Ariyan, Charlotte, MD
A Phase I Study of AM0010 in Patients with Advanced Solid Tumors
[Protocol 13-224]
Autio, Karen, MD
A Phase III Study of Surgery Followed by Radiation Therapy or Observation in Patients with Neurotropic Melanoma of the Head and Neck
[Protocol 13-248]
Barker, Christopher, MD
Targeted Silica Nanoparticles for Image-Guided Sentinel Lymph Node Mapping During Surgery in Patients with Melanoma of the Head and Neck
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-249]
Bradbury, Michelle, MD
A Phase II Study of Vorinostat for Metastatic Uveal Melanoma
[Protocol 12-027]
Carvajal, Richard, MD
A Phase II Study of Trametinib with and without GSK2141795 in Patients with Advanced Uveal Melanoma
[Protocol 13-144]
Chapman, Paul, MD
A Phase II Study of Crizotinib in Patients with High-Risk Uveal Melanoma
[Protocol 14-063]
Chapman, Paul, MD
An Expanded Access Program with Nivolumab and Ipilimumab for Patients with Inoperable or Metastatic Melanoma
[Protocol 14-200]
Chapman, Paul, MD
A Phase II Study of Dabrafenib After Surgery in Patients with BRAF V600 Mutation-Positive Stage IIIC Melanoma
[Protocol 12-124]
Chapman, Paul, MD
A Phase I Study of Vemurafenib in Adolescents with Inoperable Stage IIIC/IV Melanoma with V600 BRAF Mutations
Newly Diagnosed & Relapsed/Refractory
[Protocol 11-198]
Dunkel, Ira, MD
A Phase II Study of Ipilimumab in Children and Adolescents with Stage III/IV Inoperable Melanoma
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-043]
Dunkel, Ira, MD
A Phase I/IIA Study of Dabrafenib in Children with Advanced BRAF Mutation-Positive Solid Tumors
[Protocol 13-016]
Dunkel, Ira, MD
A Phase I Study of CB-839 in Patients with Advanced Solid Tumors
[Protocol 14-111]
Harding, James, MD
A Phase I Study of HDM201 in Patients with Advanced Cancers and a Normal TP53 Gene
[Protocol 14-139]
Hyman, David, MD
A Phase II Study of Dasatinib in Patients with Inoperable Locally Advanced or Metastatic c-KIT-Positive Acral or Mucosal Melanoma
[Protocol 13-100]
Leitao, Mario, MD
A Pilot Study of PET Imaging of Solid Tumors Using Radioactive Iodine-Labeled Hu3F8
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-147]
Modak, Shakeel, MD
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael, MD
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230)) in Patients with Advanced Uveal Melanoma
[Protocol 10-123]
Postow, Michael, MD
A Phase III Study of MEK162 versus Dacarbazine in Patients with Inoperable or Metastatic Melanomas with NRAS Q61 Mutations: The NEMO Trial
[Protocol 13-083]
Postow, Michael, MD
A Phase I Study of MEDI4736 in Patients with Advanced Solid Tumors
[Protocol 12-179]
Segal, Neil, MD, PhD
A Phase I Study of Lirilumab plus Nivolumab in Patients with Advanced Solid Tumors
[Protocol 12-224]
Segal, Neil, MD, PhD
A Phase I Study of BVD-523 in Patients with Advanced Cancers
[Protocol 13-254]
Varghese, Anna, MD
A Phase I Study of IMCgp100 in Patients with Advanced Melanoma
[Protocol 14-152]
Wolchok, Jedd, MD, PhD
A Study of the Biologic Effects of Nivolumab (BMS-936558) in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-231]
Wolchok, Jedd, MD, PhD